<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699357</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC12019111</org_study_id>
    <nct_id>NCT04699357</nct_id>
  </id_info>
  <brief_title>The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial</brief_title>
  <official_title>Shanghai Eye Disease Prevention and Treatment Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Eye Disease Prevention and Treatment Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Eye Disease Prevention and Treatment Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to evaluate the efficacy of different concentrations of atropine eye drops in&#xD;
      controlling the progression (diopter, axial length) of high myopia in young children, and to&#xD;
      compare the compliance, adverse reaction and regression rate of different concentrations of&#xD;
      atropine eye drops in myopia control.&#xD;
&#xD;
      Intervention: Group 1 (0.01% atropine group), Group 2 (0.04% atropine group), Group 3 (0.1%&#xD;
      atropine group). During the 2-year intervention period after entering the group, each&#xD;
      concentration of atropine eye drops were given every night at a fixed time before going to&#xD;
      bed, one drop each time, implemented by parents (supervision), and the wechat small program&#xD;
      was completed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of spherical equivalent</measure>
    <time_frame>at least 3 years</time_frame>
    <description>Spherical equivalent as measured by cycloplegia autorefraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of axial length</measure>
    <time_frame>at least 3 years</time_frame>
    <description>AL was measured as the distance from the anterior corneal surface to the retinal pigment epithelium (RPE) using IOLMaster or Lenstar</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">357</enrollment>
  <condition>High Myopia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.01% atropine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.04% atropine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1% atropine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The BCVA of distant vision is at least 0.5, near vision is at least 1.0, Titmus stereo&#xD;
             vision is less than 80 seconds, far exotropia is less than 10 prism degrees, far&#xD;
             esotropia is less than 6-8 prism degrees, and astigmatism is equal to or less than -&#xD;
             2.50 D;&#xD;
&#xD;
          -  Myopia progressed more than 0.5D in the past year;&#xD;
&#xD;
          -  Have normal thinking and language communication skills, and be able to actively&#xD;
             cooperate with the treatment as required;&#xD;
&#xD;
          -  Written informed consent of guardian and child.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diseases of the study eye: keratitis, keratoconus, congenital cataract, glaucoma,&#xD;
             fundus diseases; present situation with anterior segment or posterior segment&#xD;
             inflammation, such as acute conjunctivitis, iridocyclitis;&#xD;
&#xD;
          -  Systemic diseases affecting drug use: albinism, epilepsy, serious mental and&#xD;
             neurological diseases, congenital heart disease, arrhythmia;&#xD;
&#xD;
          -  Atropine allergy;&#xD;
&#xD;
          -  Very low birth weight infants with birth weight less than 1500g;&#xD;
&#xD;
          -  Receiving other treatment to control the development of myopia, including&#xD;
             anticholinergic drugs such as atropine, or participated in other functional frame&#xD;
             lens, multifocal soft lens in the past one year;&#xD;
&#xD;
          -  Other situations that not suitable for participating in the trial as judged by the&#xD;
             researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xun Xu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xun Xu, MD</last_name>
    <phone>+86-021-63240090</phone>
    <email>drxuxun@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangui He, PhD</last_name>
    <email>xianhezi@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Eye Disease Prevention &amp; Treatment Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

